Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Pharmaceuticals Is Soaring Today

By Prosper Junior Bakiny – Jun 23, 2020 at 12:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech company announced a contract with the U.S. Department of Defense.

What happened?

On Tuesday morning, Inovio Pharmaceuticals (INO -3.39%) announced that it had won a $71 million contract with the U.S. Department of Defense (DOD) to scale up the manufacturing of its Cellectra 3PSP smart devices. The DOD will also acquire some of Inovio's Cellectra 2000 devices as part of the deal. Both of these devices are used to administer INO-4800 -- Inovio's potential vaccine for COVID-19 -- directly into the patient's skin. As a result of this announcement, the company's shares are rising sharply today, and are up by 22.4% as of 12:03 p.m. EDT. 

So what

According to Inovio, when INO-4800 is administered with the Cellectra 3PSP device, "the vaccine prompts the body's immune system to drive a robust immune response." The device boasts several attractive features, too. For instance, it's small, portable, easy to use, and able to be "stockpiled in large quantities without maintenance."

Note that this isn't the first time Inovio received funding from a third party to help advance the manufacturing of its proprietary Cellectra 3PSP device. Back in March, the company received a grant of $5 million from the Bill & Melinda Gates Foundation to speed up the testing and scaling-up of the device. 

Nurse holding test tube with blood for coronavirus testing

Image source: Getty Images.

Now what

Inovio has long been a leader in the hunt for a COVID-19 vaccine. The company is currently running a phase 1 clinical trial for its investigational vaccine. The trial enrolled 40 healthy adult volunteers, each of whom will receive two doses of the INO-4800 vaccine 28 days apart. The trial will test the vaccine's safety and immunogenicity (its ability to trigger an immune response in the body). The biotech company expects results from this trial by the end of the month. Inovio also plans on starting a phase 2/3 trial, which will test the vaccine's efficacy, later this summer. As a result of its efforts to develop a vaccine for COVID-19, Inovio's shares are up by about 484% year to date.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.71 (-3.39%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.